Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce Jacobs sold 7,576 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $88.93, for a total transaction of $673,733.68. Following the completion of the transaction, the chief financial officer directly owned 237,483 shares in the company, valued at $21,119,363.19. This trade represents a 3.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Kymera Therapeutics Trading Down 0.3%

Shares of KYMR traded down $0.24 on Wednesday, reaching $86.11. 1,043,150 shares of the company’s stock were exchanged, compared to its average volume of 809,415. The business has a 50 day moving average price of $78.69 and a two-hundred day moving average price of $66.27. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00. The stock has a market capitalization of $7.03 billion, a P/E ratio of -23.40 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same period in the prior year, the firm posted ($0.88) EPS. Kymera Therapeutics’s revenue was down 60.8% on a year-over-year basis. Equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on KYMR. BTIG Research cut their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. B. Riley Financial lifted their price target on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Jefferies Financial Group upped their price target on shares of Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Truist Financial increased their price objective on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Stephens boosted their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $119.50.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KYMR. Smartleaf Asset Management LLC grew its stake in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Kymera Therapeutics during the fourth quarter worth approximately $63,000. PNC Financial Services Group Inc. raised its position in shares of Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares in the last quarter. Finally, Bessemer Group Inc. raised its position in shares of Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.